Odrade Gondry, Vicky Caveliers, Catarina Xavier, Laurens Raes, Marian Vanhoeij, Guy Verfaillie, Christel Fontaine, Katrien Glorieus, Jacques De Grève, Sofie Joris, Ine Luyten, Karen Zwaenepoel, Frederik Vandenbroucke, Wim Waelput, Sheeno Thyparambil, Ilse Vaneycken, Julie Cousaert, Sophie Bourgeois, Nick Devoogdt, Lode Goethals, Hendrik Everaert, Frank De Geeter, Tony Lahoutte, Marleen Keyaerts
Human epidermal growth factor receptor 2 (HER2) status is used for decision-making in breast carcinoma treatment. The status is obtained through immunohistochemistry or in situ hybridization. These two methods have the disadvantage of necessitating tissue sampling, which is prone to error due to tumor heterogeneity or interobserver variability. Whole-body imaging might be a solution to map HER2 expression throughout the body. Methods: Twenty patients with locally advanced or metastatic breast carcinoma (5 HER2-positive and 15 HER2-negative patients) were included in this phase II trial to assess the repeatability of uptake quantification and the extended safety of the [68 Ga]Ga-NOTA-anti-HER2 single-domain antibody (sdAb)...
February 1, 2024: Journal of Nuclear Medicine